Lilly Moves Ahead With Retevmo Launch In A Challenging Environment
Executive Summary
The company secured FDA approval for selpercatinib in RET-driven NSCLC and thyroid cancer, months ahead of the PDUFA date. Oncology president Anne White talked to Scrip about the launch.
You may also be interested in...
Lilly May Face Q2 Blues As Prior Stocking Takes Effect
Changing payer mix in diabetes due to the impacts of COVID-19 may be a central focus of Lilly's second quarter earnings call.
Roche Backs Blueprint's Precision Therapy Pralsetinib To Challenge Lilly
The collaboration between the Swiss major and Blueprint Medicines, which could be worth up to $1.7bn, should help pralsetinib provide stiff competition to Eli Lilly's RET mutation drug Retevmo.
Keeping Track: Targeted Oncologics Take Center Stage, Led By Retevmo And Tabrecta Approvals
The latest oncology news and highlights from the Pink Sheet’s FDA Performance Tracker.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports